Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates
Open Access
- 1 December 2015
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (12) , 7805-7810
Abstract
Ethionamide (ETH) is an antibiotic used for the treatment of multidrug-resistant (MDR) tuberculosis (TB) (MDR-TB), and its use may be limited with the emergence of resistance in the Mycobacterium tuberculosis population. ETH resistance in M. tuberculosis is phenomenon independent or cross related when accompanied with isoniazid (INH) resistance. In most cases, resistance to INH and ETH is explained by mutations in the inhA promoter and in the following genes: katG , ethA , ethR , mshA , ndh , and inhA . We sequenced the above genes in 64 M. tuberculosis isolates ( n = 57 ETH-resistant MDR-TB isolates; n = 3 ETH-susceptible MDR-TB isolates; and n = 4 fully susceptible isolates). Each isolate was tested for susceptibility to first- and second-line drugs using the agar proportion method. Mutations were observed in ETH-resistant MDR-TB isolates at the following rates: 100% in katG , 72% in ethA , 45.6% in mshA , 8.7% in ndh , and 33.3% in inhA or its promoter. Of the three ETH-susceptible MDR-TB isolates, all showed mutations in katG ; one had a mutation in ethA , and another, in mshA and inhA . Finally, of the four fully susceptible isolates, two showed no detectable mutation in the studied genes, and two had mutations in mshA gene unrelated to the resistance. Mutations not previously reported were found in the ethA , mshA , katG , and ndh genes. The concordance between the phenotypic susceptibility testing to INH and ETH and the sequencing was 1 and 0.45, respectively. Among isolates exhibiting INH resistance, the high frequency of independent resistance and cross-resistance with ETH in the M. tuberculosis isolates suggests the need to confirm the susceptibility to ETH before considering it in the treatment of patients with MDR-TB.Keywords
This publication has 40 references indexed in Scilit:
- Polymorphisms in Isoniazid and Prothionamide Resistance Genes of the Mycobacterium tuberculosis ComplexAntimicrobial Agents and Chemotherapy, 2011
- Precise Null Deletion Mutations of the Mycothiol Synthesis Genes Reveal Their Role in Isoniazid and Ethionamide Resistance in Mycobacterium smegmatisAntimicrobial Agents and Chemotherapy, 2011
- Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Comparative Study on Genotypic and Phenotypic Second-Line Drug Resistance Testing of Mycobacterium tuberculosis Complex IsolatesJournal of Clinical Microbiology, 2010
- Multicenter Evaluation of Bactec MGIT 960 System for Second-Line Drug Susceptibility Testing of Mycobacterium tuberculosis ComplexJournal of Clinical Microbiology, 2009
- Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosisMolecular Microbiology, 2008
- Biological and Molecular Characteristics of Mycobacterium tuberculosis Clinical Isolates with Low-Level Resistance to Isoniazid in JapanJournal of Clinical Microbiology, 2008
- Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2006
- Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosisJournal of Clinical Microbiology, 2006
- Mutations in katG , inhA , and ahpC Genes of Brazilian Isoniazid-Resistant Isolates of Mycobacterium tuberculosisJournal of Clinical Microbiology, 2003